<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Delasoie, Joachim</dc:creator>
  <dc:creator>Rossier, Jérémie</dc:creator>
  <dc:creator>Haeni, Laetitia</dc:creator>
  <dc:creator>Rothen-Rutishauser, Barbara</dc:creator>
  <dc:creator>Zobi, Fabio</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Herein we report the synthesis of a new biomaterial designed for targeted delivery of  poorly water-soluble inorganic anticancer drugs, with a focus on colorectal cancer.  Diatomaceous earth microparticles derived from marine microalgae were coated with  vitamin B12 (cyanocobalamin) as a tumor targeting agent and loaded with the well- known anticancer agents cisplatin, 5-fluorouracil (5-FU), and a tris-tetraethyl[2,2′- bipyridine]-4,4′-diamine–ruthenium(II) complex. The successful functionalization of the  biomaterial was demonstrated by different analytical techniques and by synthesizing  an organometallic fluorescein analogue of cyanocobalamin detectable by confocal  laser scanning microscopy. The drug releasing properties were evaluated for all three  species. We found that while cisplatin and 5-FU are rapidly lost from the material, the  ruthenium complex showed an unprecedented release profile, being retained in the  material up to 5 days in aqueous media but readily released in lipophilic environments  as in the cell membrane. The increased adherence of the B12 coated diatoms to  colorectal cancer cell line HT-29 and breast cancer cell line MCF-7 was demonstrated  in vitro. In both cases, the adherence of the B12 modified diatoms was at least 3 times  higher than that of the unmodified ones and was correlated with the increased  transcobalamin II (TC(II)) and transcobalamin II receptor (TC(II)-R) expression of the  targeted tissue. Our results suggest that this type of B12 modified diatoms could be a  promising tool to achieve targeted delivery of water insoluble inorganic complexes to  tumor tissues by acting as a micro-shuttle interacting with the sites of interest before  delivering the drug in the vicinity of the tumor tissue.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/309222</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/309222/files/zob_str.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/309222/files/zob_str_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1039/C8DT02914H</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Dalton Transactions. - 2018, vol. 47, no. 48, p. 17221–17232</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Slow-targeted release of a ruthenium anticancer agent from vitamin B 12 functionalized marine diatom microalgae</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
